Moderna's Q4 2025 Earnings: What to Expect

Core Insights - Moderna, Inc. is a biotechnology company focused on messenger RNA therapeutics and vaccines, currently valued at $15.9 billion [1] Financial Performance - Analysts expect Moderna to report a loss of $2.79 per share for Q4 2025, a decrease of 11.6% from $2.50 per share in the same quarter last year [2] - For the full year, the expected loss per share is $7.93, which is an increase of 10.6% from $8.87 in fiscal 2024, and a further rise to $6.88 is anticipated in fiscal 2026 [3] Stock Performance - Over the past 52 weeks, Moderna's stock has increased by 13.2%, underperforming the S&P 500 Index's gains of 16.7%, but outperforming the Health Care Select Sector SPDR Fund's returns of 11.7% [4] - The underperformance is attributed to declining demand for COVID vaccines, with expectations of a revenue decrease of 20% to 40% due to lower global vaccination rates [5] Recent Developments - On November 6, 2025, Moderna's shares rose over 3% after reporting Q3 results, with a loss per share of $0.51, significantly better than the expected loss of $2.15, and revenue of $1 billion, exceeding forecasts of $860.1 million [6] Analyst Ratings - The consensus opinion on Moderna stock is cautious, with a "Hold" rating from 24 analysts; two recommend "Strong Buy," 19 suggest "Hold," one advises "Moderate Sell," and two recommend "Strong Sell" [7] - Currently, Moderna trades above its mean price target of $35.15, with a Street-high price target of $135 indicating a potential upside of 243% [7]